Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 6/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | KIF11 | P52732 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.44 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.44 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30448099 | 0.98 | CHRM3 (0.55) | CHRM3CHRM2KCNH2LMNACYP2D6 | |
| SCHEMBL18248596 | 0.93 | CHRM3 (0.54) | CHRM3CHRM2KCNH2LMNACYP2D6 | |
| SCHEMBL7643094 | 0.93 | CHRM3 (0.54) | CHRM3CHRM2KCNH2LMNACYP2D6 | |
| SCHEMBL18248486 | 0.93 | CHRM3 (0.54) | CHRM3CHRM2KCNH2LMNACYP2D6 | |
| SCHEMBL9295790 | 0.89 | CHRM3 (0.59) | CHRM3CHRM2KCNH2LMNACYP2D6 | |
| Phosphoric Acid SCHEMBL3688742 | 0.88 | CHRM2 (0.49) | CHRM3CHRM2KCNH2LMNACYP2D6 | |
| Phosphoric Acid SCHEMBL29728497 | 0.88 | CHRM2 (0.49) | CHRM3CHRM2KCNH2LMNACYP2D6 | |
| SCHEMBL27572321 | 0.85 | OPRM1 (0.49) | CHRM3CHRM2KCNH2LMNACYP2D6 | |
| SCHEMBL18248603 | 0.85 | SOAT1 (0.49) | CHRM3CHRM2KCNH2LMNACYP2D6 | |
| SCHEMBL18248520 | 0.85 | SOAT1 (0.49) | CHRM3CHRM2KCNH2LMNACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023247697-A1 | NOVEL IRON-BASED COMPOUNDS, PROCESSES FOR THE PREPARATION THEREOF, AND USE THEREOF AS CATALYSTS | Universite Paris-Saclay (FR) | 2023-12-28 | — | — | WO | disclosed |
| US-20230225973-A1 | MULTI-LAYERED MEDICAMENT FOR INHALATION | MYLAN PHARMA UK LIMITED (GB) | 2023-07-20 | — | — | US | disclosed |
| EP-4171524-A1 | MULTI-LAYERED MEDICAMENT FOR INHALATION | Mylan Pharma UK Limited (GB) | 2023-05-03 | — | — | EP | disclosed |
| WO-2021260437-A1 | MULTI-LAYERED MEDICAMENT FOR INHALATION | MYLAN PHARMA UK LIMITED (GB) | 2021-12-30 | — | — | WO | disclosed |
| US-8268881-B2 | Carboxamide derivatives as muscarinic receptor antagonists | PFIZER LIMITED (GB) | 2012-09-18 | — | — | US | disclosed |
| US-7772223-B2 | 5-Methyl-5-(3-phenoxyazetidin-1-yl)-2,2-diphenylhexanamide, used for the treatment of respiratory system disorders such as asthma, chronic obstructive pulmonary disease, adult respiratory distress syndrome, bronchitis and emphysema | PFIZER INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-20100029720-A1 | Carboxamide Derivatives As Muscarinic Receptor Antagonists | GLOSSOP PAUL ALAN | 2010-02-04 | — | — | US | disclosed |
| US-20070105831-A1 | Carboxamide derivatives as muscarinic receptor antagonists | PFIZER LIMITED | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105831-A1 | Carboxamide derivatives as muscarinic receptor antagonists | CHRM3, CHRM5, CHRM2 | CHRM3 1/4885CHRM2 3/4885KCNH2 383/4885 |
| US-20230225973-A1 | MULTI-LAYERED MEDICAMENT FOR INHALATION | NDUFB5, NDUFB7, NDUFB8 | CHRM3 31/4885CHRM2 166/4885KCNH2 2656/4885 |
| US-20100029720-A1 | Carboxamide Derivatives As Muscarinic Receptor Antagonists | CHRM3, CHRM5, CHRM2 | CHRM3 1/4885CHRM2 3/4885KCNH2 383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.